Edition:
United States

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

2.16USD
4:00pm EDT
Change (% chg)

$0.14 (+6.93%)
Prev Close
$2.02
Open
$2.06
Day's High
$2.17
Day's Low
$2.05
Volume
273,853
Avg. Vol
433,831
52-wk High
$3.84
52-wk Low
$1.93

PDLI.OQ

Chart for PDLI.OQ

About

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $334.43
Shares Outstanding(Mil.): 165.56
Dividend: --
Yield (%): --

Financials

  PDLI.OQ Industry Sector
P/E (TTM): 5.21 57.54 29.95
EPS (TTM): 0.39 -- --
ROI: 6.19 -0.41 13.21
ROE: 8.79 6.21 14.38

Merck to pay PDL BioPharma $19.5 million to settle patent lawsuit

Merck & Co Inc has agreed to pay $19.5 million to resolve a lawsuit claiming its cancer immunotherapy drug Keytruda infringed a patent held by PDL BioPharma Inc.

5:37pm EDT

BRIEF-PDL BioPharma announces settlement of Keytruda lawsuit with Merck

* PDL BioPharma announces settlement of Keytruda patent infringement lawsuit with Merck

7:14am EDT

BRIEF-Pdl Biopharma qtrly loss per share $0.06

* Board of directors has authorized repurchase of up to $30 million of company's common stock through march 2018

Mar 01 2017

BRIEF-PDL Biopharma announces $30 mln share repurchase program

* PDL Biopharma Inc - company's board of directors has authorized repurchase of up to $30 million of company's common stock through March 2018

Mar 01 2017

BRIEF-PDL BioPharma says board authorized repurchase of up to $30 mln of stock through March 2018

* Pdl biopharma inc- company's board of directors has authorized repurchase of up to $30 million of company's common stock through march 2018 Source text for Eikon: Further company coverage:

Mar 01 2017

BRIEF-PDL BioPharma issues $150.0 mln of 2.75 pct convertible senior notes

* PDL BioPharma issues $150.0 million of 2.75 pct convertible senior notes due 2021 Source text for Eikon: Further company coverage:

Nov 22 2016

BRIEF-PDL BioPharma modifies Direct Flow financing proposal from equity investment to loan - SEC filing

* Company is evaluating its alternatives regarding its investment in Direct Flow Medical in light of modified proposal- SEC filing

Nov 17 2016

BRIEF-PDL Biopharma announces proposed $150 mln public offering of new convertible senior notes due 2021

* Expects to enter into a capped call transaction with royal bank of canada, which is the sole structuring advisor for offering

Nov 15 2016

BRIEF-PDL BioPharma qtrly earnings per share $0.08

* PDL BioPharma announces third quarter 2016 financial results

Nov 03 2016

More From Around the Web

Earnings vs. Estimates